DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
The newly issued patent, US Patent No. 11,957,647, provides both expanded scope of protection as well as longer patent term
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
Late-breaking data to be featured in an oral presentation at the American Association for Cancer Research (AACR) annual meeting on Monday, April 8 and highlighted as part of the official meeting press program
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
Aurigene.AI is an end-to-end solution for small molecule drug discovery
This partnership combines Tata Elxsi's design and technology expertise along with Dräger's expertise in medical and safety technology
The drug will target specific genetic mutations prevalent in certain types of cancers
Subscribe To Our Newsletter & Stay Updated
